Uncategorized
FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’
While drugmakers and other stakeholders want to see faster approvals, experts say the FDA’s Commissioner’s National Priority Review voucher program is still bereft of important details, with candidate selection and interference from the agency’s senior leaders topping the list.